The association between atrial fibrillation and stroke is well-known by use of the CHA2DS2VASc risk assessment. However, little is known about the thromboembolic risk in patients who have isolated systolic heart failure (HF) with sinus rhythm. Despite growing literature which shows how HF in the setting of normal sinus rhythm is a risk factor for thromboembolic disease, the recommendation for use of anticoagulation, whether warfarin or direct oral anticoagulation (DOAC) in this setting, is not yet reflected in cardiology guidelines. To reduce the risk of thromboembolism, anticoagulation trials have been done but have not conclusively shown benefit over risk. We present a case of left middle cerebral artery (MCA) stroke after de novo HF in a patient with sinus rhythm, who was previously not on anticoagulation. Case: A 57-year-old male presented to our hospital with worsening shortness of breath for 3 days. He had signs of hypervolemia consistent with an acute heart failure exacerbation. Pertinent physical exam findings included lower extremity edema, rales, and jugular venous distension. He also had fatigue and exertional dyspnea. During his hospital course, he underwent imaging studies that revealed cardiomegaly, absence of pulmonary embolism, and a severely reduced ejection fraction. During his acute heart failure admission, he developed a left MCA stroke suspected to be of cardioembolic etiology and was successfully treated with tissue plasminogen activator (tPA). Conclusion: According to the most recent AHA/ACC cardiovascular disease guidelines, anticoagulation is not indicated in systolic heart failure patients with sinus rhythm. However, our case is rare because the patient had no underlying risk factors for thromboembolism and significant past medical history. He developed new-onset nonischemic cardiomyopathy complicated by a stroke. Therefore, we suggest the need for prophylactic anticoagulation should be assessed on an individual basis, with the assistance of shared decision making, especially when the ejection fraction is acutely and severely reduced.
| [1] | Zeitler, E. P., & Eapen, Z. J. (2015). Anticoagulation in Heart Failure: a Review. J Atr Fibrillation, 8(1), 1250. |
| [2] | Sivri, N., Yetkin, E., Tekin, G. O., Yalta, K., & Waltenberger, J. (2014). Anticoagulation in patients with left ventricular systolic dysfunction and sinus rhythm: when? Clin Appl Thromb Hemost, 20(7), 729-734.View Article PubMed |
| [3] | Schumacher, K., Kornej, J., Shantsila, E., & Lip, G. (2018). Heart Failure and Stroke. Current heart failure reports, 15(5), 287-296.View Article PubMed PubMed |
| [4] | Siliste, R. N., Antohi, E. L., Pepoyan, S., Nakou, E., & Vardas, P. (2018). Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice. Eur J Heart Fail, 20(6), 978-988.View Article PubMed |
| [5] | Beggs, S.A., Rorth, R., Gardner, R.S., &McMurray, J. J. (2019). Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart, heartjnl-2018.View Article PubMed |
| [6] | Berger, J. S., Peterson, E., Laliberte, F., Germain, G., Lejeune, D., Schein, J., . . . Weir, M. R. (2019). Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. J Card Fail, 25(6), 436-447.View Article PubMed |
| [7] | Abdul-Rahim, A. H., Perez, A. C., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., . . . Investigators, G.-H. F. G.-H. C. a. (2015). Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. Circulation, 131(17), 1486-1494; discussion 1494.View Article PubMed |
| [8] | Hai, J. J., Chan, P. H., Chan, Y. H., Fong, C. H., Huang, D., Li, W. H., . . . Siu, C. W. (2016). Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry. PLoS One, 11(12), e0169095.View Article PubMed PubMed |
| [9] | Melgaard, L., Gorst-Rasmussen, A., Lane, D. A., Rasmussen, L. H., Larsen, T. B., & Lip, G. Y. (2015). Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA, 314(10), 1030-1038.View Article PubMed |
| [10] | Avellana, P., Segovia, J., Ferrero, A., Vazquez, R., Brugada, J., Borras, X., . . . Cinca, J. (2012). Anticoagulation therapy in patients with heart failure due to systolic dysfunction and sinus rhythm: analysis of REDINSCOR registry. Rev Esp Cardiol (Engl Ed), 65(8), 705-712. doi:10.1016/j.recesp.2011.11.012View Article PubMed |
| [11] | Kang, S. H., Kim, J., Park, J. J., Oh, I. Y., Yoon, C. H., Kim, H. J., . . . Choi, D. J. (2017). Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol, 248, 182-187.View Article PubMed |
| [12] | Vaduganathan, M., Patel, R. B., & Yancy, C. W. (2016). Stroke prevention in heart failure and sinus rhythm: where do we go from here? Eur J Heart Fail, 18(10), 1267-1269.View Article PubMed |
| [13] | Ferreira, J. P., Girerd, N., Gregson, J., Latar, I., Sharma, A., Pfeffer, M. A., . . . Initiative, H.-R. M. I. D. (2018). Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. J Am Coll Cardiol, 71(7), 727-735.View Article PubMed |
| [14] | Kim, W., & Kim, E. J. (2018). Heart Failure as a Risk Factor for Stroke. J Stroke, 20(1), 33-45.View Article PubMed PubMed |
| [15] | Hung, W. W. (2015). CHA 2 DS 2-VASc Score Modestly Predicts Ischemic Stroke, Thromboembolic Events, and Death in Patients with Heart Failure Without Atrial Fibrillation. Journal of Clinical Outcomes Management, 22(11). |
| [16] | Nair A, Sealove B, Halperin JL, Webber G, Fuster V. Anticoagulation in patients with heart failure: who, when, and why? Eur Hear J Suppl. 2006; 8(suppl_E):E32-E38.View Article |
| [17] | Greenberg, B., Neaton, J. D., Anker, S. D., Byra, W. M., Cleland, J. G. F., Deng, H., . . . Zannad, F. (2019). Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol, 4(6), 515-523.View Article PubMed |
| [18] | Haeusler, K. G., Endres, M., & Doehner, W. (2017). Relevance of heart failure in prevention, treatment and prognosis of ischemic stroke. Neurology International Open, 1(02), E61-E64.View Article |